Angiosarcoma of the Retroperitoneum: Report on a Patient Treated with Sunitinib
Changhoon Yoo,
Jeong-Eun Kim,
Shin-Kyo Yoon,
Song Cheol Kim,
Jin-Hee Ahn,
Tae Won Kim,
Cheolwon Suh,
Jae-Lyun Lee
Affiliations
Changhoon Yoo
Department of Internal medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul 138-736, South Korea
Jeong-Eun Kim
Department of Internal medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul 138-736, South Korea
Shin-Kyo Yoon
Department of Internal medicine, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul 138-736, South Korea
Song Cheol Kim
Department of Surgery, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul 138-736, South Korea
Jin-Hee Ahn
Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul 138-736, South Korea
Tae Won Kim
Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul 138-736, South Korea
Cheolwon Suh
Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul 138-736, South Korea
Jae-Lyun Lee
Department of Oncology, Asan Medical Center, University of Ulsan, College of Medicine, 388-1 Pungnap2-dong, Songpa-gu, Seoul 138-736, South Korea
A 52 year-old woman presented with an incidentally detected retroperitoneal angiosarcoma and multiple hepatic metastases. After chemotherapy with weekly paclitaxel and doxorubicin, angiosarcoma had progressed rapidly. Because few chemotherapeutic options were available for her, sunitinib (37.5 mg/day, daily) as a salvage regimen was administered. Although sunitinib was interrupted after two weeks due to hematologic abnormalities, some metastatic nodules were regressed. Therefore, sunitinib was recommenced at a reduced dose (25 mg/day, daily). Serial computed tomography scans showed variable response in each tumor, however, sunitinib at least delayed tumor progression, compared to previous chemotherapy. With this case report, we suggest sunitinib may be effective against angiosarcomas. When sunitinib is administered to patients with angiosarcomas, hematologic abnormalities should be monitored frequently as severe hematologic toxicity may be caused either by sunitinib per se or angiosarcoma.
